PROCESS-SYSTEMS-ENTERPRI
At the 5th Advanced Process Modelling (APM) Forum in London this week, companies from across the process industries presented on topics ranging from accelerating development of the next generation of drugs to identifying hundreds of millions of Euros in operational savings in natural gas production.
Organised and hosted by Process Systems Enterprise (PSE), providers of the gPROMS APM platform, the two-day conference is a key event for process industry organisations focused on creating sustainable value through the application of high-accuracy predictive process modelling and optimisation.
In the sessions on formulated products, aimed at the pharmaceuticals, food & beverage, consumer goods and specialty chemicals sectors, presentations from AstraZeneca, Danone, Eli Lilly, Roche, Saint-Gobain, and Solvay described how new ‘digital design’ techniques are improving drug product manufacture, including development of robust continuous manufacturing processes, and accelerating time-to-market for new formulations.
A key event was the preview of PSE’s forthcoming gPROMS FormulatedProductsTM environment for integrated design and optimisation of formulated products and their manufacturing processes. Developed in co-operation with specialists from several sectors, this allows scientists and engineers to screen formulations for end-user attributes, determine whether they can be manufactured efficiently, and then use the gPROMS platform's optimisation capabilities to optimise the whole formulation and manufacturing chain.
In the oil & gas, chemicals, petrochemical & refining sessions, where presenters included Bharat Petroleum, BP Exploration, DSM, Primetals, SABIC, SCG Chemicals, Shell, Sulzer, Velocys and Yara International, the focus was on large-scale optimisation applications capable of improving profit by tens or hundreds of millions of Euros. These included major new developments in oilfield optimisation capable of identifying millions of dollars a day in increased production, Shell's work on region-wide optimisation of natural gas processing facilities, Bharat Petroleum’s innovative work in real-time optimisation of refinery crude transition, and DSM’s operational optimisation of the utility systems supplying electricity and steam to large-scale industrial sites. SABIC described how model-based analysis helped reduce the time to screen anti-coking technologies for ethylene production from years to months.
PSE MD Costas Pantelides said, “A key focus of the conference has been the coming of age of equation-oriented (EO) process modelling tools. EO is a disruptive technology that for the first time makes it possible to optimise large-scale, complex process systems using high-fidelity models and apply techniques such as global system analysis to explore the design and operational space much more rapidly than previously possible. This is enabling companies to realise large gains in competitive advantage and dramatically accelerate innovation”.
Keynote speaker Peter Drogt of DSM, standing in for Dorus van der Linden, said that advanced process modelling is crucial technology for the organisation to accelerate innovation and quantify process decisions. A key reason for the company’s move to APM is the ability to have a single unified modelling platform across the process lifecycle.
Editors: www.psenterprise.com/news/pr160422.html
View source version on businesswire.com: http://www.businesswire.com/news/home/20160422005717/en/
Contact:
Process Systems Enterprise
Kate Burness
+44-20-8563-0888
k.burness@psenterprise.com
Link:
Social Media:
https://www.facebook.com/pages/Process-Systems-Enterprise-Limited-PSE/194030330653358?ref=bookmarks
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
